Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBL-202
- Development stage
- Preclinical
- Lead developer
- Inflection Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**IBL-202** is a first-in-class, orally available small molecule dual inhibitor of PIM kinases and PI3 kinases (PI3K) developed by Inflection Biosciences for hematologic malignancies. It demonstrates potent cytotoxicity against cancer cells in hypoxic tumor-like conditions, overcomes microenvironment-mediated resistance, and shows synergy with venetoclax by inducing apoptosis, cell-cycle arrest, and overcoming apoptotic escape mechanisms. Preclinical data support its activity across aggressive B-cell malignancies, mature T-cell lymphoma (mTCL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and acute myeloid leukemia (AML).[1][2][3][5][10]
02
Targets
PI3K (Phosphoinositide-3-kinase regulatory subunit 6)TTK (TTK protein kinase)JNK (Mitogen-activated protein kinase kinase kinase family)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)
Beyond the preview
Go deeper on IBL-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBL-202.